Research Scholar, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, 600117, Chennai, India.
Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, Chennai, India.
Int J Antimicrob Agents. 2020 May;55(5):105967. doi: 10.1016/j.ijantimicag.2020.105967. Epub 2020 Apr 4.
The Wuhan outbreak of novel Corona virus infection has been the global focus since December 2019. This infection has become a global pandemic. It is highly important to understand the virology of the pathogen and to explore the therapeutic options for management of this pandemic. Drug repurposing strategies are being considered for management of COVID 19. Among the identified drugs, Baricitinib has become a keen interest for researchers because of its ability to inhibit the viral assembly by the prevention of Clarithrin associated endocytosis. We tried to explore the reasons on why Baricitinib is not an ideal option for COVID 19.
自 2019 年 12 月以来，武汉新型冠状病毒感染疫情一直是全球关注的焦点。此次感染已成为全球性大流行。了解病原体的病毒学特性并探索这种大流行的治疗选择非常重要。正在考虑重新利用药物来治疗 COVID-19。在已确定的药物中，巴利昔替尼因其能够通过阻止克拉里丁相关内吞作用来抑制病毒组装而成为研究人员关注的焦点。我们试图探讨为什么巴利昔替尼不是治疗 COVID-19 的理想选择。
